NASDAQ:PIRS - Pieris Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$5.92 -0.01 (-0.17 %)
(As of 05/20/2018 02:01 PM ET)
Previous Close$5.92
Today's Range$5.85 - $6.01
52-Week Range$3.83 - $9.75
Volume313,571 shs
Average Volume549,466 shs
Market Capitalization$319.53 million
P/E Ratio-14.80
Dividend YieldN/A
Beta1.72

About Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals logoPieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids. The company is involved in developing PRS-343, a bispecific protein that is in Phase I clinical trial for oncology diseases; PRS-332, a bispecific anticalin-antibody fusion protein that is in preclinical evaluation stage for oncology diseases; PRS-080 that is in Phase IIa clinical trial to target hepcidin for the treatment of functional iron deficiency in anemic patients with chronic kidney disease or in end-stage renal disease patients requiring dialysis; and PRS-060, a drug candidate, which is in Phase I clinical trial that binds to the IL- 4Ra receptor for the treatment of asthma and other inflammatory diseases, as well as other drugs. It has strategic partnerships with Les Laboratoires Servier and Institut de Recherches Internationales Servier, AstraZeneca AB, and Seattle Genetics Inc., as well as others; and non-strategic license or option agreements with Aska Pharmaceutical Co., Ltd., F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc., Sanofi Group, Allergan Sales, LLC, Allergan, Inc., and Allergan Pharmaceuticals Holdings (Ireland) Unlimited Company, as well as license agreements with TUM, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Pieris Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Receive PIRS News and Ratings via Email

Sign-up to receive the latest news and ratings for PIRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PIRS
CUSIPN/A
Phone857-246-8998

Debt

Debt-to-Equity RatioN/A
Current Ratio3.03
Quick Ratio3.03

Price-To-Earnings

Trailing P/E Ratio-14.80
Forward P/E Ratio-12.33
P/E GrowthN/A

Sales & Book Value

Annual Sales$25.27 million
Price / Sales12.64
Cash FlowN/A
Price / CashN/A
Book Value$0.94 per share
Price / Book6.30

Profitability

EPS (Most Recent Fiscal Year)($0.40)
Net Income$-17,640,000.00
Net Margins-65.40%
Return on Equity-96.56%
Return on Assets-15.25%

Miscellaneous

Employees68
Outstanding Shares53,970,000

Pieris Pharmaceuticals (NASDAQ:PIRS) Frequently Asked Questions

What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) issued its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.17) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.03) by $0.15. The biotechnology company had revenue of $4.15 million for the quarter, compared to analyst estimates of $11.39 million. Pieris Pharmaceuticals had a negative return on equity of 96.56% and a negative net margin of 65.40%. View Pieris Pharmaceuticals' Earnings History.

What price target have analysts set for PIRS?

6 analysts have issued 1 year price targets for Pieris Pharmaceuticals' stock. Their forecasts range from $9.00 to $13.00. On average, they anticipate Pieris Pharmaceuticals' share price to reach $11.50 in the next twelve months. View Analyst Ratings for Pieris Pharmaceuticals.

Who are some of Pieris Pharmaceuticals' key competitors?

Who are Pieris Pharmaceuticals' key executives?

Pieris Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen S. Yoder, CEO, Pres & Director (Age 42)
  • Dr. Allan Reine, Sr. VP, CFO & Treasurer (Age 43)
  • Dr. Louis A. Matis, Sr. VP & Chief Devel. Officer (Age 67)
  • Mr. Claus Schalper MBA, Co-Founder & Sr. Advisor
  • Mr. Ahmed Mousa, VP of Licensing, IP & Legal Affairs and Corp. Compliance Officer

Has Pieris Pharmaceuticals been receiving favorable news coverage?

Headlines about PIRS stock have been trending somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pieris Pharmaceuticals earned a daily sentiment score of 0.14 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 47.05 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (6.67%), Millennium Management LLC (3.38%), BlackRock Inc. (3.34%), Omega Fund Management LLC (1.45%), Prosight Management LP (1.05%) and Northern Trust Corp (0.66%). Company insiders that own Pieris Pharmaceuticals stock include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis, Orbimed Advisors Llc and Stephen S Yoder. View Institutional Ownership Trends for Pieris Pharmaceuticals.

Which major investors are selling Pieris Pharmaceuticals stock?

PIRS stock was sold by a variety of institutional investors in the last quarter, including Omega Fund Management LLC. View Insider Buying and Selling for Pieris Pharmaceuticals.

Which major investors are buying Pieris Pharmaceuticals stock?

PIRS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, BVF Inc. IL, Prosight Management LP, BlackRock Inc., Allianz Asset Management GmbH, Wedge Capital Management L L P NC, Platinum Investment Management Ltd. and Baird Financial Group Inc.. Company insiders that have bought Pieris Pharmaceuticals stock in the last two years include Allan Reine, Darlene M Deptula-Hicks, James A Geraghty, Louis Matis and Stephen S Yoder. View Insider Buying and Selling for Pieris Pharmaceuticals.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $5.92.

How big of a company is Pieris Pharmaceuticals?

Pieris Pharmaceuticals has a market capitalization of $319.53 million and generates $25.27 million in revenue each year. The biotechnology company earns $-17,640,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Pieris Pharmaceuticals employs 68 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The biotechnology company can be reached via phone at 857-246-8998 or via email at [email protected]


MarketBeat Community Rating for Pieris Pharmaceuticals (PIRS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about Pieris Pharmaceuticals and other stocks. Vote "Outperform" if you believe PIRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PIRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pieris Pharmaceuticals (NASDAQ:PIRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Pieris Pharmaceuticals in the last 12 months. Their average twelve-month price target is $11.50, suggesting that the stock has a possible upside of 94.26%. The high price target for PIRS is $13.00 and the low price target for PIRS is $9.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.50$11.50$10.00$9.00
Price Target Upside: 94.26% upside61.97% upside25.16% upside64.53% upside

Pieris Pharmaceuticals (NASDAQ:PIRS) Consensus Price Target History

Price Target History for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ:PIRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/10/2018HC WainwrightSet Price TargetBuy$12.00LowView Rating Details
5/4/2018CowenInitiated CoverageOutperformHighView Rating Details
3/19/2018Evercore ISIInitiated CoverageOutperform ➝ Outperform$13.00HighView Rating Details
3/19/2018Jefferies GroupInitiated CoverageBuy ➝ Buy$12.00HighView Rating Details
1/17/2018William BlairInitiated CoverageOutperformHighView Rating Details
5/30/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$9.00HighView Rating Details
4/12/2017OppenheimerSet Price TargetBuy$9.00LowView Rating Details
9/28/2016Roth CapitalReiterated RatingBuy$6.00N/AView Rating Details
(Data available from 5/20/2016 forward)

Earnings

Pieris Pharmaceuticals (NASDAQ:PIRS) Earnings History and Estimates Chart

Earnings by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ:PIRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.23)$0.36($0.01)
Q2 20183($0.20)($0.13)($0.17)
Q3 20183($0.21)($0.14)($0.18)
Q4 20183($0.22)($0.14)($0.18)

Pieris Pharmaceuticals (NASDAQ PIRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2018Q1 2018($0.0270)($0.1740)$11.39 million$4.15 millionViewN/AView Earnings Details
3/9/2018Q4 2017($0.04)$0.17$7.63 million$18.15 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.21)($0.1590)$1.52 million$3.93 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.14)($0.23)$3.75 million$1.85 millionViewN/AView Earnings Details
5/10/2017Q1 2017$0.16($0.19)$32.30 million$1.34 millionViewN/AView Earnings Details
3/22/2017Q4 2016($0.13)($0.16)$1.10 million$2.73 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.13)($0.14)$1.12 million$0.79 millionViewN/AView Earnings Details
8/10/2016Q216($0.15)($0.14)$1.08 million$1.07 millionViewN/AView Earnings Details
5/11/2016Q116($0.12)($0.10)$6.40 million$1.25 millionViewN/AView Earnings Details
3/23/2016Q415($0.12)($0.07)$3.27 million$2.14 millionViewN/AView Earnings Details
11/11/2015Q315($0.11)($0.10)$0.23 million$0.42 millionViewN/AView Earnings Details
8/12/2015Q215($0.14)($0.12)$0.25 million$0.16 millionViewN/AView Earnings Details
5/13/2015Q1 2015($0.19)($0.13)$1.00 million$0.22 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pieris Pharmaceuticals (NASDAQ:PIRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.05%
Institutional Ownership Percentage: 49.81%
Insider Trading History for Pieris Pharmaceuticals (NASDAQ:PIRS)
Institutional Ownership by Quarter for Pieris Pharmaceuticals (NASDAQ:PIRS)

Pieris Pharmaceuticals (NASDAQ PIRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2018James A GeraghtyDirectorBuy10,000$5.75$57,500.0020,000View SEC Filing  
4/30/2018Orbimed Advisors LlcInsiderSell1,000,000$6.35$6,350,000.00View SEC Filing  
2/13/2018Orbimed Advisors LlcMajor ShareholderSell7,897$8.98$70,915.06View SEC Filing  
1/3/2018Orbimed Advisors LlcMajor ShareholderSell1,709,620$7.35$12,565,707.00View SEC Filing  
12/18/2017Orbimed Advisors LlcMajor ShareholderSell147,635$5.70$841,519.50View SEC Filing  
8/17/2017Allan ReineInsiderBuy65,000$4.82$313,300.0045,000View SEC Filing  
8/17/2017James A GeraghtyDirectorBuy10,000$4.82$48,200.0010,000View SEC Filing  
6/14/2016Louis MatisSVPBuy10,000$1.70$17,000.002,085View SEC Filing  
6/13/2016Darlene M Deptula-HicksCFOBuy5,000$1.66$8,300.005,000View SEC Filing  
6/13/2016Stephen S YoderCEOBuy6,000$1.68$10,080.006,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pieris Pharmaceuticals (NASDAQ PIRS) News Headlines

Source:
DateHeadline
Pieris Pharmaceuticals Inc (PIRS) Expected to Earn Q2 2018 Earnings of ($0.13) Per SharePieris Pharmaceuticals Inc (PIRS) Expected to Earn Q2 2018 Earnings of ($0.13) Per Share
www.americanbankingnews.com - May 17 at 6:44 AM
James A. Geraghty Acquires 10,000 Shares of Pieris Pharmaceuticals Inc (PIRS) StockJames A. Geraghty Acquires 10,000 Shares of Pieris Pharmaceuticals Inc (PIRS) Stock
www.americanbankingnews.com - May 16 at 10:18 AM
Zacks: Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Post Quarterly Sales of $12.85 MillionZacks: Analysts Anticipate Pieris Pharmaceuticals Inc (PIRS) Will Post Quarterly Sales of $12.85 Million
www.americanbankingnews.com - May 16 at 3:44 AM
Zacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.16 Per ShareZacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 14 at 9:35 AM
Form 8-K PIERIS PHARMACEUTICALS, For: May 10Form 8-K PIERIS PHARMACEUTICALS, For: May 10
www.streetinsider.com - May 12 at 5:53 PM
Pieris Pharmaceuticals (PIRS) Releases  Earnings ResultsPieris Pharmaceuticals (PIRS) Releases Earnings Results
www.americanbankingnews.com - May 11 at 10:33 PM
Edited Transcript of PIRS earnings conference call or presentation 10-May-18 12:00pm GMTEdited Transcript of PIRS earnings conference call or presentation 10-May-18 12:00pm GMT
finance.yahoo.com - May 11 at 8:28 AM
Pieris Pharmaceuticals (PIRS) CEO Stephen Yoder on Q1 2018 Results - Earnings Call TranscriptPieris Pharmaceuticals' (PIRS) CEO Stephen Yoder on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:56 PM
Pieris Pharmaceuticals (PIRS) Given a $12.00 Price Target by HC Wainwright AnalystsPieris Pharmaceuticals (PIRS) Given a $12.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 10 at 5:37 PM
Pieris Pharmaceuticals misses by $0.15, misses on revenuePieris Pharmaceuticals misses by $0.15, misses on revenue
seekingalpha.com - May 10 at 8:25 AM
Pieris Pharmaceuticals: 1Q Earnings SnapshotPieris Pharmaceuticals: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:25 AM
Pieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate UpdatePieris Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 10 at 8:25 AM
Pieris Pharmaceuticals (PIRS) Stock Rating Lowered by BidaskClubPieris Pharmaceuticals (PIRS) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - May 9 at 8:52 AM
Pieris Pharmaceuticals (PIRS) Now Covered by CowenPieris Pharmaceuticals (PIRS) Now Covered by Cowen
www.americanbankingnews.com - May 4 at 6:11 PM
Pieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care ConferencePieris Pharmaceuticals to Present at 43rd Annual Deutsche Bank Health Care Conference
finance.yahoo.com - May 3 at 8:17 AM
Pieris Pharmaceuticals (PIRS) Stock Rating Upgraded by ValuEnginePieris Pharmaceuticals (PIRS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 2 at 10:54 PM
Pieris Pharmaceuticals Inc (PIRS) Insider Sells $6,350,000.00 in StockPieris Pharmaceuticals Inc (PIRS) Insider Sells $6,350,000.00 in Stock
www.americanbankingnews.com - May 2 at 7:22 PM
Pieris Pharmaceuticals to Host First Quarter 2018 Investor Call and Corporate Update on May 10, 2018Pieris Pharmaceuticals to Host First Quarter 2018 Investor Call and Corporate Update on May 10, 2018
finance.yahoo.com - May 1 at 8:26 AM
Pieris Pharmaceuticals Inc (PIRS) Given Average Recommendation of "Buy" by AnalystsPieris Pharmaceuticals Inc (PIRS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 30 at 5:34 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $11.39 MillionPieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $11.39 Million
www.americanbankingnews.com - April 28 at 1:56 AM
Zacks: Analysts Expect Pieris Pharmaceuticals Inc (PIRS) Will Post Earnings of -$0.02 Per ShareZacks: Analysts Expect Pieris Pharmaceuticals Inc (PIRS) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 26 at 9:20 PM
National Research (NRCIA) & Pieris Pharmaceuticals (PIRS) Financial ReviewNational Research (NRCIA) & Pieris Pharmaceuticals (PIRS) Financial Review
www.americanbankingnews.com - April 18 at 11:06 PM
Pieris Pharmaceuticals (PIRS) vs. National Research (NRCIB) Financial SurveyPieris Pharmaceuticals (PIRS) vs. National Research (NRCIB) Financial Survey
www.americanbankingnews.com - April 18 at 5:27 AM
BidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to BuyBidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to Buy
www.americanbankingnews.com - April 15 at 10:34 PM
Head-To-Head Survey: Pieris Pharmaceuticals (PIRS) vs. Exelixis (EXEL)Head-To-Head Survey: Pieris Pharmaceuticals (PIRS) vs. Exelixis (EXEL)
www.americanbankingnews.com - April 12 at 1:09 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $11.39 MillionPieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $11.39 Million
www.americanbankingnews.com - April 11 at 1:44 AM
Zacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.02 Per ShareZacks: Brokerages Expect Pieris Pharmaceuticals Inc (PIRS) Will Announce Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 9 at 11:15 PM
HC Wainwright Analysts Give Pieris Pharmaceuticals (PIRS) a $9.00 Price TargetHC Wainwright Analysts Give Pieris Pharmaceuticals (PIRS) a $9.00 Price Target
www.americanbankingnews.com - April 6 at 4:17 PM
Pieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Buy" by BrokeragesPieris Pharmaceuticals Inc (PIRS) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 5 at 3:34 PM
Pieris Pharmaceuticals (PIRS) Cut to Sell at BidaskClubPieris Pharmaceuticals (PIRS) Cut to Sell at BidaskClub
www.americanbankingnews.com - April 5 at 12:30 AM
Pieris Pharmaceuticals (PIRS) Raised to Buy at ValuEnginePieris Pharmaceuticals (PIRS) Raised to Buy at ValuEngine
www.americanbankingnews.com - April 3 at 10:43 AM
Short Interest in Pieris Pharmaceuticals Inc (PIRS) Expands By 58.2%Short Interest in Pieris Pharmaceuticals Inc (PIRS) Expands By 58.2%
www.americanbankingnews.com - March 30 at 4:01 AM
Pieris Pharmaceuticals (PIRS) Price Target Raised to $12.00 at HC WainwrightPieris Pharmaceuticals (PIRS) Price Target Raised to $12.00 at HC Wainwright
www.americanbankingnews.com - March 28 at 3:12 PM
Pieris Pharmaceuticals (PIRS) Now Covered by Analysts at William BlairPieris Pharmaceuticals (PIRS) Now Covered by Analysts at William Blair
www.americanbankingnews.com - March 27 at 7:27 PM
Pieris Pharmaceuticals (PIRS) Upgraded at BidaskClubPieris Pharmaceuticals (PIRS) Upgraded at BidaskClub
www.americanbankingnews.com - March 25 at 2:34 PM
$11.39 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter$11.39 Million in Sales Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - March 25 at 3:46 AM
-$0.02 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter-$0.02 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - March 23 at 11:14 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Post Q1 2018 Earnings of $0.36 Per SharePieris Pharmaceuticals Inc (PIRS) Expected to Post Q1 2018 Earnings of $0.36 Per Share
www.americanbankingnews.com - March 21 at 7:00 AM
Pieris Pharmaceuticals (PIRS) Now Covered by Analysts at Jefferies GroupPieris Pharmaceuticals (PIRS) Now Covered by Analysts at Jefferies Group
www.americanbankingnews.com - March 19 at 5:34 PM
Pieris Pharmaceuticals (PIRS) Now Covered by Evercore ISIPieris Pharmaceuticals (PIRS) Now Covered by Evercore ISI
www.americanbankingnews.com - March 19 at 9:13 AM
Pieris Pharma (PIRS) Defended at JMP Securities, Sees Weakness as Buying Opportunity - StreetInsider.comPieris Pharma (PIRS) Defended at JMP Securities, Sees Weakness as Buying Opportunity - StreetInsider.com
www.streetinsider.com - March 19 at 8:23 AM
Edited Transcript of PIRS earnings conference call or presentation 9-Mar-18 1:00pm GMTEdited Transcript of PIRS earnings conference call or presentation 9-Mar-18 1:00pm GMT
finance.yahoo.com - March 18 at 8:18 AM
BidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to HoldBidaskClub Downgrades Pieris Pharmaceuticals (PIRS) to Hold
www.americanbankingnews.com - March 17 at 6:23 AM
Pieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of "Buy" from AnalystsPieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - March 11 at 5:54 PM
Pieris Pharmaceuticals (PIRS) Buy Rating Reaffirmed at HC WainwrightPieris Pharmaceuticals' (PIRS) Buy Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - March 9 at 9:02 PM
Pieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $7.63 MillionPieris Pharmaceuticals Inc (PIRS) Expected to Post Quarterly Sales of $7.63 Million
www.americanbankingnews.com - March 8 at 3:30 AM
-$0.04 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter-$0.04 EPS Expected for Pieris Pharmaceuticals Inc (PIRS) This Quarter
www.americanbankingnews.com - March 6 at 7:18 PM
Pieris Pharmaceuticals to Present at Investor Conferences in MarchPieris Pharmaceuticals to Present at Investor Conferences in March
finance.yahoo.com - March 6 at 5:40 PM
446,371 Shares in Pieris Pharmaceuticals Inc (PIRS) Acquired by Arrowstreet Capital Limited Partnership446,371 Shares in Pieris Pharmaceuticals Inc (PIRS) Acquired by Arrowstreet Capital Limited Partnership
www.americanbankingnews.com - March 6 at 4:34 AM
Bogle Investment Management L P DE Raises Holdings in Pieris Pharmaceuticals Inc (PIRS)Bogle Investment Management L P DE Raises Holdings in Pieris Pharmaceuticals Inc (PIRS)
www.americanbankingnews.com - March 5 at 5:42 AM

SEC Filings

Pieris Pharmaceuticals (NASDAQ:PIRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pieris Pharmaceuticals (NASDAQ:PIRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pieris Pharmaceuticals (NASDAQ PIRS) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.